Prostate cancer decisions — 2020

The Board has found that additional development is needed before the claims can be adjudicated on the merits. The RO must attempt to obtain VA treatment records from Overton Brooks VA Medical Center and private medical providers, including Dr. M. Dhawan in Shreveport, Louisiana.

The Veteran's prostate cancer evaluation was reduced from 100% to 40%, effective October 1, 2017. The Board is remanding both the reduction issue and the SMC status determination due to procedural issues.

The Veteran's service-connected conditions, including coronary artery disease, prostate cancer, depressive disorder, and insomnia, rendered him unable to secure or follow substantially gainful employment. The Board granted a TDIU rating effective from the date of the August 2015 RO decision.

The Board has granted an initial 20 percent evaluation for residuals of prostate cancer, effective February 2, 2010. The Veteran was shown to have nocturia two to three times a night in VA treatment records.

The Veteran's appeal is remanded for further development to address his service-connected PTSD, dysuria, and abdominal scars.

The Board has granted service connection for ischemic heart disease and prostate cancer on a presumptive basis due to herbicide agent exposure. Service connection for diabetes mellitus and hypertension is denied, while chronic renal disease remains in dispute.

The Veteran's prostate cancer is granted service connection based on herbicide exposure during his Vietnam-era service at Ubon Royal Thai Air Force Base. The Veteran's Parkinson's disease claim is remanded for further examination and opinion.

The Veteran's claims for service connection, increased rating, and TDIU have been granted. However, the issue of a compensable evaluation for colon cancer remains pending.

The Board has remanded the Veteran's claims for service connection due to exposure to herbicides, including Agent Orange. The AOJ is instructed to attempt to obtain the Veteran’s complete service treatment records and verify his reported exposure to herbicides during his time in Germany.

The Veteran's death from prostate cancer is granted as service connection due to presumed exposure to herbicide agents during his time in Vietnam.

The Board has remanded several issues related to the Veteran's service connection claims, including an earlier effective date for diabetes and increased ratings for prostate cancer. The psychiatric disorder claim is also being remanded.

The Veteran's prostate cancer residuals are rated at 40 percent from June 1, 2015 to November 21, 2018 and at 60 percent thereafter. A TDIU is granted effective from November 21, 2018.

The Veteran's claims for effective dates prior to September 20, 2013 for service connection for prostate cancer, diabetic peripheral neuropathy of the sciatic nerve of the left lower extremity, diabetic peripheral neuropathy of the sciatic nerve of the right lower extremity, erectile dysfunction, and diabetes have been denied.,The Veteran's claims for effective dates prior to September 20, 2013 for service connection for prostate cancer, diabetic peripheral neuropathy of the sciatic nerve of the left lower extremity, diabetic peripheral neuropathy of the sciatic nerve of the right lower extremity, erectile dysfunction, and diabetes have been denied.,The Veteran's claims for effective dates prior to September 20, 2013 for service connection for prostate cancer, diabetic peripheral neuropathy of the sciatic nerve of the left lower extremity, diabetic peripheral neuropathy of the sciatic nerve of the right lower extremity, erectile dysfunction, and diabetes have been denied.,The Veteran's claims for effective dates prior to September 20, 2013 for service connection for prostate cancer, diabetic peripheral neuropathy of the sciatic nerve of the left lower extremity, diabetic peripheral neuropathy of the sciatic nerve of the right lower extremity, erectile dysfunction, and diabetes have been denied.,The Veteran's claims for effective dates prior to September 20, 2013 for service connection for prostate cancer, diabetic peripheral neuropathy of the sciatic nerve of the left lower extremity, diabetic peripheral neuropathy of the sciatic nerve of the right lower extremity, erectile dysfunction, and diabetes have been denied.

The Board has remanded the case due to insufficient information regarding the Veteran's exposure to herbicides during service, specifically while stationed at Ubon RTAFB. The RO is instructed to contact JSRRC for verification and provide a formal finding if necessary.

The Veteran's PTSD is granted, and his prostate cancer is granted with a 60% initial rating. The right ankle disability claim is reopened based on new evidence. The coronary heart disease claim is remanded for further examination. Tinnitus and the right ankle disability claims are also remanded.

The Board has remanded the case due to insufficient evidence regarding whether the Veteran's cause of death, metastatic esophageal cancer, was related to Agent Orange exposure during service or caused by his service-connected prostate cancer.

The Board has remanded the service connection claims for a heart disability and prostate cancer due to insufficient evidence regarding the Veteran's exposure to Agent Orange during his service in Korea.

Your claims for service connection for prostate cancer and diabetes mellitus, type II have already been granted in a March 2020 rating decision. The Board has dismissed your appeal as these grants of service connection constitute a full award of the benefits sought.

The Board has remanded the case due to insufficient development of records and need for an addendum opinion regarding service connection for various conditions, including those related to exposure at Camp Lejeune.

The Board has remanded the claims for prostate cancer, colon cancer, and ischemic heart disease due to potential exposure to ionizing radiation during service. The RO must request a review of the Veteran's claim file for this development under VA regulations.